Sarepta Therapeutics: A $2B Business Priced Like It's Broken [Seeking Alpha]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Seeking Alpha
FY25 revenue grew 16% to $2.2 billion, but profitability deteriorated sharply due to surging R&D, inventory write-downs, and manufacturing issues, resulting in a $713 million GAAP net loss. Regulatory setbacks for Elevidys, including a restricted label and safety concerns, have compressed SRPT's valuation and introduced significant execution risk and revenue unpredictability. I maintain a Hold rating, citing limited near-term visibility, but see long-term optionality in gene therapy and the expanding siRNA pipeline, with 2026 as a pivotal year for key data readouts. sturti/E+ via Getty Images Thesis Strategically, I think Sarepta Therapeutics' ( SRPT ) story is now going to be a fine balance between execution risk and long-term optionality. Elevidys is still the key value driver; it's still supported by strong three-year clinical
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 [Yahoo! Finance]Yahoo! Finance
- Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business Wire
- How FDA Review of Sarepta's ESSENCE Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics (SRPT) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $37.00 price target on the stock.MarketBeat
- Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 2/25/26 - Miss
SRPT
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- SRPT's page on the SEC website